Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline Review, H2 2017’, provides an overview of the Non Alcoholic Fatty Liver Disease (NAFLD) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Non Alcoholic Fatty Liver Disease (NAFLD) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Non Alcoholic Fatty Liver Disease (NAFLD)

The report reviews pipeline therapeutics for Non Alcoholic Fatty Liver Disease (NAFLD) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Non Alcoholic Fatty Liver Disease (NAFLD) therapeutics and enlists all their major and minor projects

The report assesses Non Alcoholic Fatty Liver Disease (NAFLD) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Non Alcoholic Fatty Liver Disease (NAFLD)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Non Alcoholic Fatty Liver Disease (NAFLD) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Akcea Therapeutics Inc

Allergan Plc

Ardelyx Inc

AstraZeneca Plc

Betagenon AB

Bird Rock Bio Inc

Boehringer Ingelheim GmbH

Can-Fite BioPharma Ltd

Cerenis Therapeutics Holding SA

CJ HealthCare Corp

Conatus Pharmaceuticals Inc

Corcept Therapeutics Inc

CymaBay Therapeutics Inc

Daewoong Pharmaceutical Co Ltd

Dimerix Bioscience Pty Ltd

Dr. Falk Pharma GmbH

DURECT Corp

Enanta Pharmaceuticals Inc

Eternygen GmbH

Galmed Pharmaceuticals Ltd

Gemphire Therapeutics Inc

Genfit SA

Gilead Sciences Inc

Huons Co Ltd

Immuron Ltd

Kyorin Pharmaceutical Co Ltd

Matinas BioPharma Holdings Inc

Metacrine Inc

Miyarisan Pharmaceutical Company Ltd

Nordic Bioscience A/S

NovaTarg Therapeutics Inc

Ocera Therapeutics Inc

Pfizer Inc

Renova Therapeutics Inc

Sancilio & Company Inc

Shenzhen HighTide Biopharmaceutical Ltd

TaiwanJ Pharmaceuticals Co Ltd

TCM Biotech International Corp

Zydus Cadila Healthcare Ltd

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Non Alcoholic Fatty Liver Disease (NAFLD) - Overview 8

Non Alcoholic Fatty Liver Disease (NAFLD) - Therapeutics Development 9

Pipeline Overview 9

Pipeline by Companies 10

Pipeline by Universities/Institutes 14

Products under Development by Companies 15

Products under Development by Universities/Institutes 18

Non Alcoholic Fatty Liver Disease (NAFLD) - Therapeutics Assessment 19

Assessment by Target 19

Assessment by Mechanism of Action 23

Assessment by Route of Administration 27

Assessment by Molecule Type 29

Non Alcoholic Fatty Liver Disease (NAFLD) - Companies Involved in Therapeutics Development 31

Akcea Therapeutics Inc 31

Allergan Plc 31

Ardelyx Inc 32

AstraZeneca Plc 32

Betagenon AB 33

Bird Rock Bio Inc 33

Boehringer Ingelheim GmbH 34

Can-Fite BioPharma Ltd 34

Cerenis Therapeutics Holding SA 35

CJ HealthCare Corp 35

Conatus Pharmaceuticals Inc 36

Corcept Therapeutics Inc 36

CymaBay Therapeutics Inc 37

Daewoong Pharmaceutical Co Ltd 37

Dimerix Bioscience Pty Ltd 38

Dr. Falk Pharma GmbH 38

DURECT Corp 39

Enanta Pharmaceuticals Inc 39

Eternygen GmbH 40

Galmed Pharmaceuticals Ltd 40

Gemphire Therapeutics Inc 41

Genfit SA 41

Gilead Sciences Inc 42

Huons Co Ltd 42

Immuron Ltd 43

Kyorin Pharmaceutical Co Ltd 43

Matinas BioPharma Holdings Inc 44

Metacrine Inc 44

Miyarisan Pharmaceutical Company Ltd 45

Nordic Bioscience A/S 45

NovaTarg Therapeutics Inc 46

Ocera Therapeutics Inc 46

Pfizer Inc 47

Renova Therapeutics Inc 47

Sancilio & Company Inc 48

Shenzhen HighTide Biopharmaceutical Ltd 48

TaiwanJ Pharmaceuticals Co Ltd 49

TCM Biotech International Corp 49

Zydus Cadila Healthcare Ltd 50

Non Alcoholic Fatty Liver Disease (NAFLD) - Drug Profiles 51

(leucine + metformin hydrochloride + sildenafil citrate) - Drug Profile 51

(leucine + PDE5 Inhibitor) - Drug Profile 53

AC-261066 - Drug Profile 54

AF-102 - Drug Profile 55

AKCEA-ANGPTL3LRx - Drug Profile 56

Aramchol - Drug Profile 58

ARI-3037MO - Drug Profile 64

AZD-4076 - Drug Profile 66

C-10 - Drug Profile 68

CBM-588 - Drug Profile 70

cenicriviroc mesylate - Drug Profile 72

CER-209 - Drug Profile 80

CJ-14199 - Drug Profile 82

CORT-118335 - Drug Profile 83

dabigatran etexilate mesylate - Drug Profile 84

DMX-300 - Drug Profile 86

Drug to Antagonize MCJ for Gastrointestinal Disorders - Drug Profile 87

DUR-928 - Drug Profile 88

DWP-10292 - Drug Profile 93

EDP-305 - Drug Profile 94

elafibranor - Drug Profile 96

emricasan - Drug Profile 105

FGF-1 Program - Drug Profile 113

FLB-12 - Drug Profile 114

gemcabene calcium - Drug Profile 115

GS-9674 - Drug Profile 120

HTD-1801 - Drug Profile 123

HU-002 - Drug Profile 124

IMM-124E - Drug Profile 125

KBP-089 - Drug Profile 128

KM-2702 - Drug Profile 129

liothyronine sodium - Drug Profile 130

MAT-8800 - Drug Profile 131

MN-002 - Drug Profile 132

naltrexone hydrochloride - Drug Profile 134

Namacizumab - Drug Profile 136

namodenoson - Drug Profile 137

ND-630 - Drug Profile 143

NLM-0100 - Drug Profile 145

norursodeoxycholic acid - Drug Profile 146

O-304 - Drug Profile 147

oltipraz - Drug Profile 149

ornithine phenylacetate - Drug Profile 150

PF-06835919 - Drug Profile 157

RDX-023 - Drug Profile 158

RT-200 - Drug Profile 159

RT-210 - Drug Profile 160

saroglitazar - Drug Profile 161

SC-410 - Drug Profile 164

seladelpar lysine - Drug Profile 165

selonsertib - Drug Profile 169

Small Molecule for Non-Alcoholic Steatohepatitis and Non-Alcoholic Fatty Liver Disease - Drug Profile 172

Small Molecules for Non-Alcoholic Steatohepatitis and Non Alcoholic Fatty Liver Disease - Drug Profile 173

Small Molecules to Activate AMPK for Fatty Liver Disease - Drug Profile 174

Small Molecules to Inhibit NaCT for Metabolic Diseases - Drug Profile 175

Synthetic Peptides for Non Alcoholic Fatty Liver Disease and Non Alcoholic Steatohepatitis - Drug Profile 176

TCM-606F - Drug Profile 177

tipelukast - Drug Profile 178

Non Alcoholic Fatty Liver Disease (NAFLD) - Dormant Projects 183

Non Alcoholic Fatty Liver Disease (NAFLD) - Discontinued Products 184

Non Alcoholic Fatty Liver Disease (NAFLD) - Product Development Milestones 185

Featured News & Press Releases 185

Appendix 197

Methodology 197

Coverage 197

Secondary Research 197

Primary Research 197

Expert Panel Validation 197

Contact Us 197

Disclaimer 198

List of Tables

List of Tables

Number of Products under Development for Non Alcoholic Fatty Liver Disease (NAFLD), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Akcea Therapeutics Inc, H2 2017

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Allergan Plc, H2 2017

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Ardelyx Inc, H2 2017

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by AstraZeneca Plc, H2 2017

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Betagenon AB, H2 2017

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Bird Rock Bio Inc, H2 2017

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Boehringer Ingelheim GmbH, H2 2017

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Can-Fite BioPharma Ltd, H2 2017

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Cerenis Therapeutics Holding SA, H2 2017

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by CJ HealthCare Corp, H2 2017

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Conatus Pharmaceuticals Inc, H2 2017

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Corcept Therapeutics Inc, H2 2017

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by CymaBay Therapeutics Inc, H2 2017

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2017

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Dimerix Bioscience Pty Ltd, H2 2017

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Dr. Falk Pharma GmbH, H2 2017

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by DURECT Corp, H2 2017

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Enanta Pharmaceuticals Inc, H2 2017

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Eternygen GmbH, H2 2017

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Galmed Pharmaceuticals Ltd, H2 2017

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Gemphire Therapeutics Inc, H2 2017

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Genfit SA, H2 2017

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Gilead Sciences Inc, H2 2017

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Huons Co Ltd, H2 2017

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Immuron Ltd, H2 2017

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2017

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Matinas BioPharma Holdings Inc, H2 2017

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Metacrine Inc, H2 2017

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Miyarisan Pharmaceutical Company Ltd, H2 2017

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Nordic Bioscience A/S, H2 2017

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by NovaTarg Therapeutics Inc, H2 2017

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Ocera Therapeutics Inc, H2 2017

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Pfizer Inc, H2 2017

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Renova Therapeutics Inc, H2 2017

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Sancilio & Company Inc, H2 2017

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Shenzhen HighTide Biopharmaceutical Ltd, H2 2017

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by TaiwanJ Pharmaceuticals Co Ltd, H2 2017

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by TCM Biotech International Corp, H2 2017

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline by Zydus Cadila Healthcare Ltd, H2 2017

Non Alcoholic Fatty Liver Disease (NAFLD) – Dormant Projects, H2 2017

Non Alcoholic Fatty Liver Disease (NAFLD) – Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Non Alcoholic Fatty Liver Disease (NAFLD), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Top 10 Molecule Types, H2 2017

Number of Products by Stage and Top 10 Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports